THE USE OF NINTEDANIB IN THE TREATMENT OF POST-COVID-19 FIBROSIS

Pulmonary fibrosis is becoming a recognized complication of coronavirus disease 2019 (COVID-19). We report 2 cases of 2 patients aged 40 and 61 with pulmonary fibrosis due to COVID-19. The clinical examination showed that the 2 patients were dyspneic with a weak oxygen saturation and that there was bilateral crackles of the two pulmonary fields. High-resolution computed tomography showed bilateral multifocal ground glass opacities, subpleural fibrotic bands (between 25-50% and 75% parenchymal involvement). We prescribed them an anti-fibrosant, nintedanib, and there was a significant clinical and radiological improvement after 15 days of treatment. Nintedanib may have a new therapeutic role in the prevention of fibrosis associated with COVID-19.